Skip to main content
HCPCS J9264 · Level II · Part B drug

J9264: paclitaxel protein-bound particles (Abraxane), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9264

Billing unit
1 MG
Paclitaxel protein bound
ASP payment limit
$3.64
October 2026; -44.7% vs July 2026
Practitioner MUE
800
MAI 3
OPPS status
SI K
APC 1712
NCCI exposure
no PTP pairs
Coverage articles
1
5 states

TL;DR

HCPCS J9264 is the Level II code for Injection, paclitaxel protein-bound particles, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $3.64 per billing unit, down 44.7% from July 2026. The practitioner MUE allows up to 800 units per date of service (MAI 3), so a full 800-unit day is $2,912.00 at the current limit. Under OPPS it carries status indicator K in APC 1712. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 11 NDCs to it, sold as Paclitaxel Protein-Bound (American Regent), Paclitaxel Protein-Bound, Paclitaxel Protein-Bound Particles by Teva Pharmaceuticals USA, Inc., American Regent, Inc., Sandoz Inc. 1 Medicare coverage article lists the code across 5 states, including A52450.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9264 at $3.64 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $6.586 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9264
QuarterPayment limitPerCoinsurance
October 2026$3.641 MG20%
July 2026$6.5861 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 11 NDCs from 11 labelers to J9264. Report the NDC in the claim's drug segment and bill the number of J9264 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J9264
NDCDrug nameLabelerPackage sizeBilling units / package
00480-3290-01Paclitaxel Protein-Bound (American Regent)Teva Pharmaceuticals USA, Inc.1 × 1100
00517-4300-01Paclitaxel Protein-BoundAmerican Regent, Inc.1 × 1100
00781-3531-91Paclitaxel Protein-Bound ParticlesSandoz Inc.1 × 1100
24979-0710-51Paclitaxel Protein-BoundTWI Pharmaceuticals, Inc.1 × 1100
60505-6230-04Paclitaxel Protein-BoundApotex Corp1 × 1100
67457-0937-50Paclitaxel Protein-Bound ParticlesMylan Institutional LLC1 × 1100
68001-0651-37Paclitaxel Protein-BoundBluePoint Laboratories1 × 1100
68817-0134-50AbraxaneCelgene Corporation1 × 1100
69097-0398-78Paclitaxel Protein-BoundCipla USA, Inc.1 × 1100
71288-0183-50Paclitaxel Protein-BoundMeitheal Pharmaceuticals Inc.1 × 1100
72603-0408-01Paclitaxel Protein-Bound ParticlesNorthstar RxLLC1 × 1100

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9264. For practitioners the limit is 800 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9264 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services8003 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital8003 Date of Service Edit: ClinicalPrescribing Information
DME supplier8003 Date of Service Edit: ClinicalPrescribing Information

MUE for J9264 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9264 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9264 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9264 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists J9264 in their HCPCS tables, covering 5 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J9264
ArticleTitleContractor(s)StatesRelated LCD
A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)Wellpoint FederalCT IL MN NY WIL33394

Diagnoses Medicare contractors cover for J9264

One billing and coding article attaches a covered diagnosis list to J9264: 699 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J9264
ICD-10-CMDescription (FY2027)Articles covering
C16.0Malignant neoplasm of cardia1 of 1
C16.1Malignant neoplasm of fundus of stomach1 of 1
C16.2Malignant neoplasm of body of stomach1 of 1
C16.3Malignant neoplasm of pyloric antrum1 of 1
C16.4Malignant neoplasm of pylorus1 of 1
C16.5Malignant neoplasm of lesser curvature of stomach, unspecified1 of 1
C16.6Malignant neoplasm of greater curvature of stomach, unspecified1 of 1
C16.8Malignant neoplasm of overlapping sites of stomach1 of 1
C17.0Malignant neoplasm of duodenum1 of 1
C17.1Malignant neoplasm of jejunum1 of 1
C17.2Malignant neoplasm of ileum1 of 1
C17.3Meckel's diverticulum, malignant1 of 1
C17.8Malignant neoplasm of overlapping sites of small intestine1 of 1
C17.9Malignant neoplasm of small intestine, unspecified1 of 1
C21.0Malignant neoplasm of anus, unspecified1 of 1
684 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J9264 are counted here. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J9264, by article
ArticleContractorGroups that applyCovered codes for J9264Full list
A52450Wellpoint Federalone list for every code in the article699On LCD L33394

Local coverage policies that list J9264

1 active Local Coverage Determination lists J9264 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9264 carries status indicator K and is assigned to APC 1712, with a published national unadjusted payment of $3.64. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9264 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $3.64 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J9264 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9264

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9264

What does HCPCS code J9264 describe?

J9264 is defined by CMS as "Injection, paclitaxel protein-bound particles, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9264 a CPT code?

No. J9264 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as paclitaxel protein-bound particles (Abraxane); CPT codes are five-character codes maintained by the AMA. On a Part B claim J9264 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9264 in October 2026?

The ASP-based payment limit is $3.64 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $6.586. Commercial payers use their own fee schedules.

How many units of J9264 can be billed per day?

The practitioner Medically Unlikely Edit is 800 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J9264?

The October 2026 ASP crosswalk lists 11 NDCs from 11 labelers: Paclitaxel Protein-Bound (American Regent) (Teva Pharmaceuticals USA, Inc.); Paclitaxel Protein-Bound (American Regent, Inc.); Paclitaxel Protein-Bound Particles (Sandoz Inc.); Paclitaxel Protein-Bound (TWI Pharmaceuticals, Inc.). For example NDC 00480-3290-01 (package size 1) equals 100 billing units of J9264.

Does J9264 have NCCI bundling edits?

No active practitioner PTP pairs list J9264 as a column-1 or column-2 code in the v323r0 release.

Which Medicare coverage articles mention J9264?

1 current Billing and Coding Article in the Medicare Coverage Database lists J9264, covering 5 states: A52450 (Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)).

What diagnosis codes support J9264?

One Medicare billing and coding article lists 699 covered ICD-10-CM codes for J9264, for example C16.0 (Malignant neoplasm of cardia); C16.1 (Malignant neoplasm of fundus of stomach); C16.2 (Malignant neoplasm of body of stomach); C16.3 (Malignant neoplasm of pyloric antrum); C16.4 (Malignant neoplasm of pylorus). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.